



Updated Monthly

July 13, 2023

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:




Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





Terms

AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aoi: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

GBG Acronyms

Updated Monthly

July 13, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine



TABLE OF CONTENTS

New Opportunities

Aging.....	2
Bioengineering.....	2
Biotechnology and Biomanufacturing.....	3
Burn Injury.....	3
Cancer.....	4
Cardiovascular and Pulmonary Health.....	4
Chronic Pain & Pain Management.....	5
Coronavirus.....	6
Defense Medical Research and Development.....	6
Endocrine and Metabolic Diseases.....	6
Environmental Health.....	7
Genomics.....	7
Health IT & Data.....	7
HIV/AIDS.....	9
Immunology & Infectious Disease.....	10
Maternal and Pediatric Health.....	12
Medical Countermeasures.....	12
Mental Health.....	12
Musculoskeletal Health.....	13

GBG Report

Updated Monthly

July 13, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

Neuroscience, Cognitive and Brain Health.....	13
Rare Diseases.....	16
Sleep Health.....	16
Substance Use Disorder.....	17
Toxic Exposures.....	18
Vision Health.....	18

Recurring Opportunities

Advanced Research Projects Agency for Health.....	19
Air Force.....	19
Army.....	20
BARDA.....	21
DARPA.....	22
Defense Threat Reduction Agency.....	22
Department of Energy.....	23
National Science Foundation.....	23
Navy.....	23



July 21, 2023 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE and open to all) then from 10:30-11am EST (premium service and private consultation for G2G and GBG customers).

The Military Health System Research Symposium will be held on August 14-17 at the Gaylord Palms in Kissimmee, FL. [Registration is open](#). G2G is hosting a webinar to share information about how to maximize your participation in MHSRS on July 18 at noon EDT. [Learn more and register here](#).

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (2)		
1.	Pre-Announcement: Resources to Promote Coordination and Collaboration across Deeply Phenotyped Longitudinal Behavioral and Social Studies of Aging (U24 CT Not Allowed) (NIH/NIA) NOT-AG-23-036	This FOA invites applications to establish a Resource Development Network focused on the infrastructure needed to promote and support coordination, collaboration, and innovation across deeply phenotyped longitudinal behavioral and social studies of aging that are rich in psychological, behavioral, and biobehavioral content. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-036.html	Up to \$1.6 million, for up to 5 years	Estimated post date: 8/15/23 Estimated proposal date: 10/31/23
2.	Development and Validation of Harmonized Methodologies to Measure NAD+ and Related Metabolites in Clinical Trials (U01 Clinical Trial Required) (NIH/NIA) RFA-AG-24-039	This NOFO invites applications to develop and validate the standardized protocols for measuring nicotinamide adenine dinucleotide (NAD+) and related metabolites levels in humans, including sample collection and storage, assays’ calibration, and standardization of measurements across different types of samples, such as plasma, tissue, or serum extracts, and validation of these protocols. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-039.html	Dependent upon proposal, for up to 5 years	Letter of intent: 10/2/23 Proposal: 11/2/23
		BIOENGINEERING (3)		
3.	Cellular and Biochemical Engineering (NSF) PD 23-1491	The Cellular and Biochemical Engineering program supports fundamental engineering research that advances understanding of cellular and biomolecular processes. CBE-funded research may lead to the development of enabling technology for advanced biomanufacturing of therapeutic cells, biochemicals, and biopharmaceuticals, and for other biotechnology industries. https://new.nsf.gov/funding/opportunities/cellular-biochemical-engineering-o	Dependent upon proposal and award mechanism	Proposals accepted anytime

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING		
4.	Disability and Rehabilitation Engineering (NSF) PD 23-5342	The Disability and Rehabilitation Engineering program supports fundamental engineering research that will improve the quality of life of persons with disabilities through the development of new theories, methodologies, technologies, or devices. https://new.nsf.gov/funding/opportunities/disability-rehabilitation-engineering-dare-2	Dependent upon proposal and award mechanism	Proposals accepted anytime
5.	Engineering of Biomedical Systems (NSF) PD 23-5345	The goal of the Engineering of Biomedical Systems (EBMS) program is to provide opportunities for fundamental and transformative research projects that integrate engineering and life sciences to solve biomedical problems and serve humanity in the long term. https://new.nsf.gov/funding/opportunities/engineering-biomedical-systems-0	Dependent upon proposal and award mechanism	Proposals accepted anytime
		BIOTECHNOLOGY AND BIOMANUFACTURING (2)		
6.	Assessing and Predicting Technology Outcomes (APTO) (NSF) NSF 23-600	APTO will fund a cohort of projects to conduct R&D in models that can accurately describe past and future outcomes including the capabilities, production, and use of specific technologies. These models will be able to predict likely outcomes for specific future technologies and what investments would reliably change or accelerate those outcomes. Key technologies include biotechnology, medical technology, genomics, and synthetic biology. https://www.nsf.gov/pubs/2023/nsf23600/nsf23600.htm	Up to \$4 million, for up to 5 years	Preliminary proposal: 8/21/23 Full proposal: 10/30/23
7.	NIIMBL Project Call 7.1 (NIIMBL)	This RFP includes member-driven and industry-led priority topic areas for technical and workforce development proposals. Topic areas include: Cell processing; Technologies for intensified processing of therapeutic proteins; Analytical and manufacturing technologies for viral vectormanufacturing. Applicants must be NIIMBL members before the full proposal deadline. https://niimbl.my.site.com/s/project-call-7-1	Up to \$750,000 Dependent on award mechanism	Concept paper: 8/3/23 Full proposal: 12/7/23
		BURN INJURY (1)		
8.	Pre-Announcement: Burn Wound Imaging Technology (HHS/BARDA) 75A50123R00002	BARDA intends to use Project BioShield (PBS) to support development of a novel burn wound imaging technology (BWIT). This technology is envisioned as a non-invasive imaging device to rapidly assess the wound size and severity and assist emergency physicians on triage decisions to more specialized burn centers. https://sam.gov/opp/de5882c8226c4cb9bc45cb76e5c2a1e3/view	Dependent upon contract	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER (3)		
9.	FY23 Breast Cancer Research Program (BCRP) Clinical Research Extension Award II (CREA2-2) (DoD/CDMRP) HT9425-23-BCRP-CREA2-2	The FY23 BCRP Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. https://cdmrp.health.mil/funding/bcrp	Up to \$6 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/12/23 Proposal: 9/26/23
10.	Advancing Cancer Control Equity Research Through Transformative Solutions (U19/U24 Clinical Trial Optional) (NIH/NCI) RFA-CA-23-026 (U19) RFA-CA-23-027 (U24)	This NOFO invites proposals for research centers to advance cancer control equity by stimulating community-engaged, multilevel research interventions that address the impact of SDOH on adverse cancer control outcomes. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-026.html (U19) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-027.html (U24)	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 8/14/23 Proposal: 9/4/23
		CARDIOVASCULAR AND PULMONARY HEALTH (6)		
11.	NOSI: Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment (NIH/NHLBI) NOT-HL-23-090	This NOSI aims to increase research to understand the heterogeneity of obesity phenotypes and the underlying mechanisms that protect against or increase risk for obesity and obesity-associated conditions. The objective of this NOSI is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-090.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/27
12.	The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional) and Data Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NHLBI/NCI) RFA-HL-24-010 (UG1) RFA-HL-24-011 (U24)	The overall goals of the BMT CTN are to identify and address gaps in HCT and adoptive cell therapy outcomes for blood diseases; rapidly disseminate study results to improve the scientific basis of the therapies being studied; provide a platform to train emerging clinical trial investigators; build a biorepository for future research that includes specimens linked to clinical data and outcomes from patients with non-malignant blood diseases who receive these therapies; and ultimately improve the life and quality of life for patients with blood diseases who receive HCT or adoptive cell therapies. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-010.html (UG1) https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-011.html (U24)	Up to \$150,000 per year, for up to 7 years (UG1) Up to \$41.8 million, for up to 7 years (U24)	Letter of intent: 9/2/23 Proposal: 10/2/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
13.	Pre-Announcement: Cardiovascular Health Topical PCORI Funding Announcement -- Cycle 3 2023 (PCORI)	This PFA will fund comparative clinical effectiveness research (CER) on key decisional dilemmas in the fields of CVD prevention, screening, diagnosis, treatment, and posttreatment recovery and studies that focus on interventions and care strategies that improve outcomes in populations experiencing disparities. https://www.pcori.org/funding-opportunities/announcement/cardiovascular-health-topical-pcori-funding-announcement-cycle-3-2023	Up to \$12 million, for up to 5 years	System opens: 9/6/23 Letter of intent: 10/3/23 Proposal: 1/9/24
		CHRONIC PAIN & PAIN MANAGEMENT (7)		
14.	FY23 Chronic Pain Management Research Program (DoD/CDMRP) HT9425-23-CPMRP-CEA HT9425-23-CPMRP-IIRA HT9425-23-CPMRP-CORA HT9425-23-CPMRP-PMCCRA	There are four awards in the FY23 CPMRP: Clinical Exploration Award, Investigator-Initiated Research Award, Clinical Outcomes Research Award, and Pain Management Collaboratory Award. Applications must address one or more Focus areas specific to each award. https://cdmrp.health.mil/funding/cpmrp	Up to \$3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/21/23 Proposal: 11/9/23
15.	HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required) (NIH) RFA-AT-24-003	This NOFO seeks research applications to develop quantitative measures of myofascial tissues and assess their abilities to detect changes to myofascial tissues across a variety of pain management interventions. https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-003.html	Up to \$500,000 per year, for up to 3 years (R61) Up to \$800,000 per year, for up to 2 years (R33)	Letter of intent: 9/1/23 Proposal: 10/18/23
16.	Evidence-Based Clinical Practice Guideline for the Management of Acute Low Back Pain (U01) CT Not Allowed (FDA/CDER) RFA-FD-23-034	The FDA seeks applications to develop, disseminate, implement, and evaluate an evidence-based Clinical Practice Guideline (CPG) for the management of acute low back pain. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-034.html	Up to \$2 million, for up to 3 years	Proposal: 8/15/23
17.	Evidence-Based Clinical Practice Guideline for the Management of Laparoscopic Abdominal Surgeries (U01) CT Not Allowed (FDA/CDER) RFA-FD-23-035	The FDA seeks applications to develop, disseminate, implement, and evaluate an evidence-based Clinical Practice Guideline (CPG) for the management of postoperative pain in patients who have undergone diagnostic and procedural laparoscopic abdominal surgeries. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-035.html	Up to \$2 million, for up to 3 years	Proposal: 8/15/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CORONAVIRUS (3)		
18.	Analysis of data in the COVID-19 Neuro Databank-Biobank (R03 - Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-24-025	This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications of COVID-19 by using this de-identified database. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-025.html	Up to \$50,000 per year, for up to 2 years	Letter of intent: 10/8/23 Proposal: 11/8/23
19.	PHASTR: Does metformin show a reduction of severe outcomes of COVID-19 or of Long COVID in the N3C Data Enclave (NIH/NCATS)	A recent clinical trial (COVID-OUT) demonstrated that metformin lowered the odds of emergency department visits, hospitalizations, or death by over 40% and also decreased the incidence of long COVID as diagnosed by a medical provider. The fundamental question being asked is: Does metformin reduce the incidence of severe outcomes of COVID-19 and/or prevent Long COVID? https://covid.cd2h.org/node/852	\$50,000, for 2 months	Proposal: 7/31/23
20.	PHASTR: Does molnupiravir show a reduction of severe outcomes of COVID-19 in the N3C Data Enclave (NIH/NCATS)	Molnupiravir has demonstrated variable effects on the risk of hospitalization or mortality among outpatients with COVID-19. The question to be addressed is: Does molnupiravir reduce the risk of hospitalization or death within one month of COVID-19 in at-risk patients with COVID-19 in the N3C population, controlling for confounding variables such as vaccination, risk factors for severe outcomes, concomitant therapy, and variant epoch. https://covid.cd2h.org/node/853	\$50,000, for 2 months	Proposal: 7/31/23
		DEFENSE MEDICAL RESEARCH AND DEVELOPMENT (1)		
21.	FY23 Combat Casualty Care Research Program (JPC-6): Trauma Immunology Research Award (DoD/CDMRP) HT9425-23-DMRDP-TIRA	The Trauma Immunology Research Award (TIRA) will support basic and applied research and early-stage development of materiel and knowledge products to address critical gaps in the understanding of immune system, immune response, immune function, and other associated host responses in combat injuries, in particular, severe polytrauma as encountered in the operational environment. https://cdmrp.health.mil/funding/jpc6	Up to \$2 million, for up to 3 years	Pre-Application: 8/15/23 Proposal: 11/9/23
		ENDOCRINE AND METABOLIC DISEASES (1)		
22.	NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-23-014	The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Divisions. Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-014.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 8/28/23 Proposal: 9/28/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENVIRONMENTAL HEALTH (1)		
23.	Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) (NIH/NIEHS) RFA-ES-23-011	This NOFO is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-011.html	Up to \$275,000, for up to 2 years	Letter of intent: 9/2/23 Proposal: 10/2/23
		GENOMICS (3)		
24.	Pre-Announcement: Broadening Opportunities for Computational Genomics and Data Science Education (UE5 Clinical Trial Not Allowed) (NIH/NHGRI) NOT-HG-23-043	This NOFO will solicit applications to support educational activities that encourage individuals from diverse backgrounds to pursue further studies or careers in computational genomics and data science research. https://www.grants.gov/web/grants/view-opportunity.html?oppId=348842	Up to \$150,000	Estimated post date: 8/7/23 Estimated proposal date: 10/10/23
25.	Data Analysis and Coordination Center for the PsychENCODE Consortium (U24 Clinical Trial Not Allowed) (NIH/NIMH) PAR-23-234	This NOFO will support a Data Analysis and Coordination Center for PsychENCODE, a NIMH consortium for the discovery and characterization of human-specific non-coding functional genomic elements across brain regions, cell types, and developmental time periods and their role(s) in the molecular pathophysiology of psychiatric disorders. https://grants.nih.gov/grants/guide/pa-files/PAR-23-234.html	Dependent upon proposal, for up to 4 years	Letter of intent: 7/24/23 Proposal: 8/24/23
26.	Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) (NIH/NHGRI) RFA-HG-23-026	This NOFO seeks applications for the development of informatics tools to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). Emphasis for this RFA will be on development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-026.html	Up to \$400,000 per year, for up to 3 years	Letter of intent: 10/1/22 Proposal: 11/1/22
		HEALTH IT & DATA (43)		
27.	NOSI: Secondary Analyses of Existing Alcohol Research Data (NIH/NIAAA) NOT-AA-23-011	This NOSI aims to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. https://grants.nih.gov/grants/guide/notice-files/NOT-AA-23-011.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/6/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA		
28.	Pre-Announcement: Early Prediction of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) Open Innovation Challenge (NIH/NIA) NOT-AG-23-040	The goal of this challenge is to deliver solutions for accurate, representative, inclusive, open, and robust early prediction of AD/ADRD. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-040.html	Total prizes of \$650,000	Estimated post date: 9/1/23 Estimated proposal date: 1/31/24
29.	NOSI: Applications of Data Science in Translational Dental, Oral, and Craniofacial Research (NIH/NIDCR) NOT-DE-23-002	This NOSI, with 33 linked grants, calls for a variety of data science-oriented projects focused on developing and using data and data science resources, methods, and tools for dental, oral, and craniofacial (DOC) research. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-23-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/26
30.	Pre-Announcement: Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) (NIH/NLM) NOT-LM-23-003	This NOFO will solicit applications to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. https://grants.nih.gov/grants/guide/notice-files/NOT-LM-23-003.html	TBD	Estimated post date: 7/28/23 Estimated proposal date: 10/5/23
31.	Interactive Digital Media (IDM) Biomedical Science Resources for Pre-College Students and Teachers (SBIR) (R43/R44 Clinical Trial Not Allowed) (NIH/NIGMS) PAR-23-213	This NOFO funds SBCs to develop innovative IDM in the areas of biomedical science supported by NIH's research mission. The products should be able to engage users for interactive learning experiences. They are expected to not only disseminate knowledge of biomedical science, but also enhance student's interest in learning more about biomedical science and related research, and to develop and strengthen student's problem-solving skills. https://grants.nih.gov/grants/guide/pa-files/PAR-23-213.html	Up to \$295,924 (Phase I)	Proposal: 9/5/23
32.	Development of Software for Data Science in Infectious and Immune-Mediated Diseases Research (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-038	This NOFO solicits applications for the development of software to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for data science research on infectious and immune-mediated diseases (IID). https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-038.html	Up to \$300,000 per year, for up to 3 years	Letter of intent: 9/11/23 Proposal: 10/11/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA		
33.	Partnerships With Common Fund Data Ecosystem Resources (U24 Clinical Trial not Allowed) (NIH Common Fund) RFA-RM-23-013	This NOFO announces the availability of funds for projects that involve collaboration with multiple CF Data Coordinating Centers (DCCs) to combine discovery and/or translational approaches with work that will enhance reusability of Common Fund data and contribute knowledge to the Common Fund Data Ecosystem. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-013.html	Up to \$500,000 per year, for up to 3 years	Letter of intent: 11/4/23 Proposal: 12/4/23
34.	2023 DataWorks! Prize (NIH)	The 2023 DataWorks! Prize will focus on best practice “recipes” that advance biological and biomedical research activities, with a focus on practices enabling robust data management during the research process. Participants will submit their data sharing/reuse best practice recipes in a form that can be used by an audience of their peers, such as a teaching resource or tool for active data management. https://www.challenge.gov/?challenge=2023-dataworks-prize	Waiver topics may exceed these amounts	Proposal: 7/24/23
		HIV/AIDS (104)		
35.	NOSI: HIV Cure-Related Research in Diverse Populations (NIH) NOT-AI-23-046	This NOSI highlights NIAID’s interest in HIV cure-related research in diverse cohorts of people living with HIV to determine similarities and differences in the establishment and dynamics of persistent non-subtype B HIV reservoirs, as well as in post-treatment control of viremia. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-046.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/26
36.	NOSI: Research on HIV-associated Malignancies (NIH/NCI) NOT-CA-23-070	This NOSI calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of these cancers, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-070.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26
37.	NOSI: Clinical Studies of CNS Complications in People with HIV (NIH/NIMH/NINDS) NOT-MH-23-255	The goal of this initiative is to understand the heterogeneity of CNS outcomes in people with HIV and to support clinical research studies to aid in the identification/validation of actionable biosignatures of adverse CNS outcomes in people with HIV. There are 34 grants linked in this NOSI. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-255.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26
38.	NOSI: Eradication of HIV-1 from Central Nervous System Reservoirs (NIH/NIMH/NINDS) NOT-MH-23-260	This NOSI, with 31 linked grants, invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-260.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
39.	NOSI: Neuropathogenesis of CNS Complications Associated with HIV (NIH/NIMH/NINDS) NOT-MH-23-280	The goals of this NOSI are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS complications in the setting of chronic viral suppression and antiretroviral therapy (ART). There are 31 grants linked in this NOSI. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-280.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26
40.	Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) (NIH/ORIP/NIMH) PAR-23-215	This NOFO will support preclinical HIV/AIDS research using NHP models performed by ESIs. The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence to develop new research directions and to position these researchers to be competitive for new research funding. https://grants.nih.gov/grants/guide/pa-files/PAR-23-215.html	Up to \$200,000 per year, for up to 2 years	Proposal: 9/7/23
41.	Precision HIV Health: Integrating Data and Implementation Science to Accelerate HIV Prevention and Treatment (R21/R33 Clinical Trial Not Allowed) (NIH/NIMH) RFA-MH-24-100	This NOFO encourages participatory data science and implementation science research to accelerate the implementation of more targeted and sustainable HIV interventions with the goals of (1) using data science methods to model complex systems to identify more targeted HIV prevention, treatment, and care interventions and implementation strategies; (2) using novel measurement approaches and modern statistical methods to evaluate the implementation of data-driven discoveries; (3) integrating meaningful engagement of community and implementing partners at every stage of the research. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-100.html	Up to \$275,000, for up to 2 years (R21) Up to \$375,000, for up to 3 years (R33)	Letter of intent: 10/22/23 Proposal: 11/22/23
		IMMUNOLOGY & INFECTIOUS DISEASE (27)		
42.	Lassa Fever Virus (LASV) Cell Sorting for Monoclonal Antibody Discovery for USAMRIID (DoD/USAMRIID) HT942523Q0059	USAMRIID has a requirement for a contract that provides for severable, non-personal services to sort peripheral blood mononuclear cells (PBMCs) from Lassa fever virus (LASV) survivors to discover and produce monoclonal antibodies for assessment in in-vitro and in-vivo assays at USAMRIID. https://sam.gov/opp/d914f9464ef44409b02b4b3dd61d0088/view	Dependent upon contract	Proposal: 8/7/23
43.	NOSI: Understanding Mucosal Immunity Against Enteric Eukaryotic Pathogens to Advance Discovery of New Interventions (NIH/NIAID) NOT-AI-23-045	This NOSI is to encourage comprehensive research efforts to better understand host-pathogen interactions and pathogen-specific immunity at mucosal sites, including infection-induced mucosal immunity at the site of infection, host target identification, antigen or immunogen discovery, and design and testing of vaccines, monoclonal antibodies (mAbs), or host-directed therapies. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-045.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/17/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
44.	NOSI: Promoting Research and Development of Vaccines Against Enteric Viruses (NIH/NIAID) NOT-AI-23-048	This NOSI is designed to encourage the research community to develop a range of approaches for vaccine research and development using both established and novel technologies with the long-term goal of developing candidates for late-stage clinical trial evaluation. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-048.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/17/26
45.	NOSI: Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives (NIH/NIAID) NOT-AI-23-049	This NOSI invites applications for research on the use of targeted protein and nonprotein degradation as it relates to the development of anti-infective strategies against viral, bacterial, and fungal pathogens and/or their toxins. Both novel monofunctional and hetero-bi/tri-functional strategies will be considered. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-049.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/17/26
46.	NOSI: Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections (NIH/NIAID) NOT-AI-23-050	This NOSI aims to stimulate advances in diagnosis and treatment of NTM infections that cause or exacerbate pulmonary disease such as <i>Mycobacterium abscessus</i> , <i>Mycobacterium avium</i> complex, and <i>Mycobacterium kansasii</i> . https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-050.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/17/26
47.	Pre-Announcement: NIH Common Fund Human Virome Program (NIH Common Fund) NOT-RM-23-014 (U24) NOT-RM-23-015 (U01) NOT-RM-23-016 (U01) NOT-RM-23-017 (U54)	The NIH Common Fund HVP's overall goal is to establish a research consortium to extensively characterize the human virome and create tools, models, methods that will enable in-depth study of its variation in relation to host factors and its influence on health and disease. These NOFOs will support tool and technology development, HVP Functional Interaction Studies, the HVP Consortium Organization and Data Collaboration Center (CODCC), and Virome Characterization Centers (VCCs). https://grants.nih.gov/grants/guide/notice-files/NOT-RM-23-014.html (U24) https://grants.nih.gov/grants/guide/notice-files/NOT-RM-23-015.html (U01) https://grants.nih.gov/grants/guide/notice-files/NOT-RM-23-016.html (U01) https://grants.nih.gov/grants/guide/notice-files/NOT-RM-23-017.html (U54)	TBD	Estimated post date: 8/4/23 Estimated proposal date: 11/29/23
48.	Advancing Development of Diagnostics for Congenital and Adult Acquired Syphilis (R21 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-039	The purpose of this NOFO is to develop new and advance existing diagnostics for congenital and adult acquired syphilis infections by leveraging recent advances in <i>Treponema pallidum</i> basic research and broader infectious disease diagnostic innovations. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-039.html	Up to \$275,000, for up to 2 years	Letter of intent: 10/2/23 Proposal: 11/2/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH (1)		
49.	Immune Mechanisms at the Maternal-Fetal Interface (R01 Clinical Trial Not Allowed) (NIH/NIAID/ORWH) RFA-AI-23-027	This NOFO seeks applications that will improve the understanding of the roles and interactions of immune cells at the maternal-fetal interface that support pregnancy and enable optimal placental development and function; and elucidate the mechanisms by which infection and/or vaccination, during gestation modulate immune responses in the pregnant individual and alter systemic or tissue-specific immunity in the offspring. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-027.html	Up to \$400,000 per year, for up to 5 years	Letter of intent: 9/11/23 Proposal: 10/11/23
		MEDICAL COUNTERMEASURES (2)		
50.	Synthetic Hemo-technologies to Locate and Disinfect (SHIELD) (DoD/DARPA) HR001123S0037	The program will develop prophylactic countermeasures effective against both bacteria and fungi, pathogens that are responsible for the vast majority of bloodstream infections (BSI). State-of-the-art countermeasures to manage BSI include antifungals and antibiotics which can be toxic, ineffective, and be administered in an untimely manner. https://sam.gov/opp/d26a1d6c9e4c4e399c61935bb75dfe35/view	Dependent upon proposal and award mechanism	Abstract: 8/2/23 Full proposal: 9/27/23
51.	CCRP Initiative: Chemical Threat Agent Exposure Resource and Coordination Core (ExRC) (U2C Clinical Trial Not Allowed) (NIH) RFA-ES-23-009	The ExRC will serve as a state-of-the-art facility to provide analytical and technical expertise to CCRP supported investigators and will serve as a resource to expose experimental models of choice to toxic chemicals to characterize molecular, cellular, and physiological pathways mediating acute injury, delayed onset of injury after acute threat agent exposure, and early-stage development of MCMs. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-009.html	Up to \$750,000 per year, for up to 5 years	Letter of intent: 8/28/23 Proposal: 9/28/23
		MENTAL HEALTH (4)		
52.	Schizophrenia and related disorders during mid- to late-life (R01/R21 Clinical Trial Optional) (NIH/NIMH) PAR-24-023 (R01) PAR-24-027 (R21)	These NOFOs encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-026.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 9/5/23 (R01) Proposal: 9/16/23 (R21)
53.	Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 CT Optional) (NIH/NIMH) PAR-24-210	This NOFO invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care. https://grants.nih.gov/grants/guide/pa-files/PAR-24-210.html	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 4/17/24 Proposal: 5/17/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
54.	Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required) (NIH/NIMH) RFA-MH-24-150	This NOFO will support one clinical trial network to evaluate biological, digital, cognitive, and clinical outcome measures in individuals at clinical high risk (CHR) for psychosis in Proof of Principle (PoP) trial(s) using a pharmacological intervention. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-150.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/17/23 Proposal: 10/17/23
		MUSCULOSKELETAL HEALTH (2)		
55.	Pre-Announcement: Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) (NIH) NOT-NS-23-090	These Centers will promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-090.html	Up to \$1 million per year, for up to 4 years	Estimated post date: 9/1/23 Estimated proposal date: 11/1/23
56.	Military Orthopaedic Medicine and Readiness Optimization Research Grant (SOMOS)	The mission of the Society is to “advance the practice of military and disaster musculoskeletal medicine through leadership, education, research, and collaboration”. As such, any grant applications to be considered must have clear and demonstrable relevance to the mission of the Society. https://www.somos.org/research-grant	Up to \$20,000, for 2 years	Letter of intent: 8/1/23 Invited proposal: 9/30/23
		NEUROSCIENCE, COGNITIVE AND BRAIN HEALTH (13)		
57.	Pre-Announcement: Community-Engaged Health Equity Research in Neuroscience Initiative (R01/R34 Clinical Trial Not Allowed) (NIH/NINDS) NOT-NS-23-070 (R01) NOT-NS-23-071 (R34)	These NOFOs will solicit applications to establish clinical trial readiness for community-driven research interventions, and for planning grants to assess feasibility and/or determine best practices to conduct community-engaged health equity research in neurological disorders with populations that experience health disparities (HDPs), that, if successful, would support, enable and/or lay the groundwork for a future clinical study or trial. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-070.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-071.html (R34)	TBD	Estimated post date: 8/18/23 Estimated proposal date: 10/18/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NEUROSCIENCE, COGNITIVE AND BRAIN HEALTH		
58.	Pre-Announcement: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3/U44 Clinical Trial Optional) (NIH) NOT-NS-23-091 (UG3/UH3) NOT-NS-23-093 (U44)	The planned NOFO reissue will encourage applications from investigators to help advance their drug discovery and development projects into the clinic. To be eligible for the BPN, an applicant must have well-validated bioactive compound(s) in hand; the BPN does not support screening for hit compounds. Projects can enter the BPN during Discovery or Development and may seek support through phase I/first-in-human testing. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-091.html (UG3/UH3) https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-091.html (U44)	TBD	Estimated post date: 10/25/23 Estimated proposal date: 2/12/24
59.	Simultaneous and Synergistic Multi-Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial not allowed) (NIH/NINDS/NIA) PAR-23-195	This NOFO aims to support the comprehensive and rigorous validation of two or more novel interacting disease modifying therapeutic targets for ADRD. This is with the goal of supporting future development of therapies reflecting the complexity of human dementia. Target validation includes experiments performed with the goal of increasing confidence that the proposed pathways, circuits, systems, etc. are causal of the disease state and that perturbing the targets could positively impact patients while maintaining safety. https://grants.nih.gov/grants/guide/pa-files/PAR-23-195.html	Up to \$499,000 per year, for up to 5 years	Letter of intent: 8/15/23 Proposal: 9/15/23
60.	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01/R21 Clinical Trial Optional) (NIH/NIMH/NIA) PAR-23-207 (R01) PAR-23-208 (R21)	These NOFOs encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with AD/ADRD. The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. https://grants.nih.gov/grants/guide/pa-files/PAR-23-207.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-23-208.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 10/5/23 (R01) Proposal: 10/16/23 (R21)
61.	Development & Characterization of Experimental models of post-TBI ADRD (R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-23-218	This NOFO aims to accelerate the development, characterization, and validation of novel mammalian models that display progressive clinical and pathological characteristics of ADRD following TBI, including chronic traumatic encephalopathy. https://grants.nih.gov/grants/guide/pa-files/PAR-23-218.html	Up to \$670,000 per year, for up to 5 years	Letter of intent: 8/22/23 Proposal: 9/22/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NEUROSCIENCE, COGNITIVE AND BRAIN HEALTH		
62.	Cellular and Molecular Biology of Complex Brain Disorders (R01/R21 Clinical Trial Not Allowed) (NIH/NIMH) PAR-24-024 (R01) PAR-24-025 (R21)	These NOFOs encourage research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. Studies may be either hypothesis-generating or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms. https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-025.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 10/5/23 (R01) Proposal: 10/16/23 (R21)
63.	Primary Care-Based Screening Tool and Intervention Development for the Detection and Prevention of Abuse and Neglect in Older and Vulnerable Adults With, or at Risk for, Mild Cognitive Impairment and AD/ADRD (R61/R33 Clinical Trial Required) (NIH/NIA) RFA-AG-24-048	This NOFO supports research that can lead to the development of primary care-based screening tools and early interventions to detect and prevent abuse and neglect (AN) in older and vulnerable adults living with, or at risk for, mild cognitive impairment (MCI) and AD/ADRD. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-048.html	Up to \$750,000, for up to 3 years (R61) Up to \$3 million, for up to 3 years (R33)	Letter of intent: 9/20/23 Proposal: 10/20/23
64.	BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) (NIH) RFA-MH-24-280	This initiative aims to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-280.html	Dependent upon proposal, for up to 3 years	Letter of intent: 5/7/24 Proposal: 6/7/24
65.	Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (NIH/NINDS/NIA) RFA-NS-24-009	This NOFO supports the optimization of promising genome editing-based therapeutic leads for AD/ADRD, towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-009.html	Up to \$650,000 per year, for up to 5 years	Proposal: 11/15/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RARE DISEASES (1)		
66.	Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (NIH/NCATS/NIMH) RFA-TR-23-016	This NOFO provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-016.html	Up to \$275,000, for up to 2 years	Letter of intent: 9/1/23 Proposal: 10/2/23
		SLEEP HEALTH (1)		
67.	Pre-Announcement: Sleep Health Topical PCORI Funding Announcement -- Cycle 3 2023 (PCORI)	This PFA will fund high-quality, comparative clinical effectiveness research (CER) projects that focus on sleep health. delivery strategies that improve cardiovascular health outcomes in populations experiencing disparities. https://www.pcori.org/funding-opportunities/announcement/sleep-health-topical-pcori-funding-announcement-cycle-3-2023	Up to \$12 million, for up to 5 years	System opens: 9/6/23 Letter of intent: 10/3/23 Proposal: 1/9/24
		SMALL BUSINESS DEVELOPMENT (9)		
68.	PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for SBIR/STTR (R41/R42/R43/R44 Clinical Trial Not Allowed/Required) (NIH/CDC/FDA) PA-23-230 PA-23-231 PA-23-232 PA-23-233	US small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) identified in these NOFOs are encouraged to submit SBIR/STTR grant applications in response to identified topics (see PHS 2023-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). https://grants.nih.gov/grants/guide/pa-files/PA-23-230.html https://grants.nih.gov/grants/guide/pa-files/PA-23-231.html https://grants.nih.gov/grants/guide/pa-files/PA-23-232.html https://grants.nih.gov/grants/guide/pa-files/PA-23-233.html	Up to \$295,924 (Phase I) Up to \$1,972,828 (Phase II) Waiver topics may exceed these amounts	Proposal: 9/5/23
69.	SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed/Required) (NIH) PAR-23-219 PAR-23-220	These NOFOs aim to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts. https://grants.nih.gov/grants/guide/pa-files/PAR-23-219.html https://grants.nih.gov/grants/guide/pa-files/PAR-23-220.html	Up to \$3,945,657, for up to 3 years Dependent upon IC limits	Letter of intent: 8/5/23 Proposal: 9/5/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
70.	Pre-Announcement: A Solicitation of the NIH and The CDC for SBIR Contract Proposals (NIH/CDC) PHS-2024-1	NIH and CDC are soliciting proposals from SBCs that possess the R&D expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and SBIR program objectives. Topics include diagnostics, therapeutics, vaccines, and health IT. View the full list of topics here. https://sam.gov/opp/f76f86b1206b4b6e9132c6cf9da3b6c0/view	Dependent upon proposal and contract	Estimated post date: 8/7/23 Estimated proposal date: 11/7/23
71.	Small Business Innovation Research Program - Phase I (USDA/NIFA) USDA-NIFA-SBIR-009962	Projects dealing with agriculturally-related manufacturing and alternative and renewable energy technologies are encouraged across all SBIR/STTR topic areas. USDA SBIR/STTR's flexible research areas ensure innovative projects consistent with USDA's vision of a healthy and productive nation in harmony with the land, air, and water. https://www.nifa.usda.gov/grants/funding-opportunities/small-business-innovation-research-small-business-technology-transfer	Up to \$181,500 for 8 months	Proposal due: 9/19/23
72.	Pre-Announcement: DOE SBIR/STTR (DoE)	Topics of this DoE SBIR/STTR release are anticipated to include: Complex Data: Advanced Data Analytic Technologies for Systems Biology and Bioenergy, Tools or Instruments for Structural or Morphological Characterization of Biological Systems Ranging from Atomic to Multi-cellular Scales, and Automated Bioimaging Devices for Structural and Functional Characterization of Plant and Microbial Communities. https://science.osti.gov/-/media/sbir/pdf/funding/2024/FY24-Phase-I-Release-1-Combined-Topics07072023.pdf	Up to \$250,000, for up to 1 year (Phase I) Up to \$1.6 million (Phase II)	Post date: 8/7/23 Letter of intent: 8/28/23 Proposal: 10/10/23
		SUBSTANCE USE DISORDER (15)		
73.	Assessment of potential substance abuse treatment medications in nonhuman primate models (NIH/NIDA) 75N95023R00047	NIDA intends to solicit proposals from qualified organizations having in-house capability to provide technical and scientific expertise to determine the effects of compounds in the following paradigms (1) drug discrimination test in nonhuman primates when tested alone or in combination with cocaine, (2) self-administration test in nonhuman primates when tested for ability to reduce cocaine, methamphetamine, or heroin self-administration or to be directly self-administered, and (3) ability to attenuate signs of opioid withdrawal in opioid dependent nonhuman primates. https://sam.gov/opp/afc4c99b930a48d2ba5ffb8b35d1df02/view	Dependent upon proposal and available funding	Proposal: 8/7/23
74.	NOSI: Xylazine: Understanding its Use and the Consequences (NIH/NIDA) NOT-DA-24-009	This NOSI aims to encourage research on the prevalence and consequences of xylazine use and the treatment of xylazine use and overdose alone or in combination with other drugs. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-009.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
75.	NOSI: Impacts of Psychedelic and Dissociative Drug Policy Changes on Public Health Outcomes (NIH/NIDCR) NOT-DA-24-010	This NOSI expresses special interest in grant applications that examine the impact of changing state and local psychedelic and dissociative drug policies. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-010.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/26
		TOXIC EXPOSURES (3)		
76.	FY23 Toxic Exposures Research Program (DoD/CDMRP) HT9425-23-TERP-CTA HT9425-23-TERP-IIRA HT9425-23-TERP-TRA	There are three awards in the FY23 TERP: Investigator-Initiated Research Award; Translational Research Award; and Clinical Trial Award. Applications must address one or more Program Goals and Topic Areas. Program Goals: Elucidate mechanisms of how military-related toxic exposures result in adverse effects; Diagnose the effects of military-related toxic exposures; Predict and prevent military-related toxic exposures; Develop therapeutics, treatments, and strategies. Topic Areas: Neurotoxin Exposure; Gulf War Illness; Airborne Hazards and Burn Pits; Other Military Service-Related Toxic Exposures in General. https://cdmrp.health.mil/funding/terp	Up to \$2.5 million, for up to 4 years Dependent upon award mechanism	Pre-application: 9/13/23 Proposal: 10/4/23
		VISION HEALTH (3)		
77.	NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) (NIH/NEI) PAR-23-200 (R61/R33) PAR-23-205 (R33)	The goal of these NOFOs is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. https://grants.nih.gov/grants/guide/pa-files/PAR-23-20.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-23-205.html (R33)	Up to \$500,000 per year, for up to 2 years (R61) Up to \$1 million per year, for up to 3 years (R33)	Letter of intent: 7/24/23 Proposal: 8/24/23
78.	Pre-Announcement: Effectiveness of Telehealth-Based Programs to Detect Glaucoma Among High-Risk Populations in Community Health Settings (CDC/ERA) RFA-DP-24-081	This NOFO will investigate the feasibility, effectiveness, and cost-effectiveness of high-quality and innovative public health interventions to improve glaucoma detection and management among high-risk populations within community-based health care delivery settings. https://www.grants.gov/web/grants/view-opportunity.html?oppId=348858	Up to \$750,000	Estimated post date: 11/28/23 Estimated proposal date: 1/27/24





Recurring Opportunities

July 13, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)		
79.	Open-Office Broad Agency Announcement (BAA) 75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems. https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		AIR FORCE (3)		
80.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
81.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
82.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
83.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
84.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
85.	USSOCOM BAA for Extramural Biomedical Research and Development W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppld=307754	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required
86.	Army Research Office Broad Agency Announcement for Fundamental Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/72a66224611942dd9215e60722caaac5/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
87.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
88.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppld=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
89.	Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
90.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppld=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
92.	BARDA Broad Agency Announcement BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; Flexible and Strategic Therapeutics (FASTx); Next-generation COVID-19 Vaccines; ImmuneChip+. https://sam.gov/opp/6f989eb9c421422788a4c3a9133917fo/view	Dependent upon proposal	White papers: 9/25/23; some AOIs due earlier



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA		
93.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #19: Healing Lungs; AOI #20: DRIVe Forward; AOI #21: Vaccines on Demand; AOI #22: ReBoot; AOI #24: REPAIR; AOI #25: FASTx. https://sam.gov/opp/caf2abe4309b4460b4979d01bocabbf2/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
94.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
95.	Defense Sciences Office, Office-wide HR001122S0041	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Global Change. https://sam.gov/opp/d99f59e0d48245e688b92af595380c79/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 8/31/23
		DEFENSE THREAT REDUCTION AGENCY (2)		
96.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
97.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
98.	FY2023 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0002844	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppld=343866	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/23
		NATIONAL SCIENCE FOUNDATION (1)		
99.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. The programs support the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund R&D, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics . https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 11/1/23
		NAVY (3)		
100.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
101.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N00014-23-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy23-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/23
102.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/58eeca6ef84a4d25b41boedaca42447a/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/23

